NASDAQ$AMLX
Amylyx Pharmaceuticals Inc · Q1 2023 earnings
Q1 2023 earnings · · Investor relations
Briefing
Reported first quarter financial results, highlighted by product revenue and progress in commercial launches and pipeline expansion.
Amylyx Pharmaceuticals reported a net product revenue of $71.4 million for the first quarter of 2023, driven by the commercial launches of RELYVRIO in the U.S. and ALBRIOZA in Canada. The company's net income for the quarter was $1.6 million, a significant improvement compared to the net loss of $47.8 million in the same period of 2022.
- First quarter 2023 product revenue was $71.4 million, driven by RELYVRIO and ALBRIOZA.
- Commercial launches of RELYVRIO in the U.S. and ALBRIOZA in Canada continued to progress.
- Regulatory review for AMX0035 is ongoing in the EU.
- Pipeline expanded with the first participant dosed in the Phase 2 HELIOS study of AMX0035 in Wolfram syndrome and planned initiation of a pivotal Phase 3 study in progressive supranuclear palsy.
Headline financials
Revenue & EPS history
Amylyx · Revenue · Quarterly
$71.4M
Forward guidance
Amylyx anticipates continued progress with RELYVRIO and ALBRIOZA, regulatory developments, and clinical trials for AMX0035.
Tailwinds
- Potential approval of AMX0035 for the treatment of ALS in the European Union.
- Ongoing commercialization of RELYVRIO and ALBRIOZA.
- Potential continued market acceptance and market opportunity for RELYVRIO and ALBRIOZA.
- Anticipated benefits of strategic new hires.
- Expectations regarding the Company’s longer-term strategy.
Headwinds
- Success, cost, and timing of Amylyx’ program development activities.
- Amylyx’ ability to successfully commercialize RELYVRIO in the United States and ALBRIOZA in Canada.
- Amylyx’ ability to execute on its commercial and regulatory strategy.
- Expectations regarding the timing of EMA review of AMX0035 for the treatment of ALS.
- Impact that the ongoing COVID-19 pandemic, global macroeconomic uncertainty and geopolitical instability will have on Amylyx’ operations.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 18 quarterly earnings reports · overlaid with Q1 2023
+0.3%
Avg return
Earnings day
+2.5%
Avg return
5 days after
+7.4%
Avg return
30 days after
44%
8 / 18 earnings
Positive
+23.4%
Q4 2021
Best reaction
-30.7%
Q3 2023
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2025 | -7.6% | -9.5% | -2.3% | |
| Q3 2025 | -5.9% | -4.2% | +7.3% | |
| Q1 2025 | -6.0% | -7.8% | +9.4% | |
| Q4 2024 | +0.3% | +29.0% | +17.0% | |
| Q3 2024 | +7.7% | +0.3% | -17.4% | |
| Q2 2024 | +1.1% | +5.9% | +26.1% | |
| Q1 2024 | -8.8% | -3.1% | -8.3% | |
| Q4 2023 | +15.3% | +24.1% | -82.1% | |
| Q3 2023 | -30.7% | -30.4% | -22.2% | |
| Q2 2023 | +0.5% | -2.3% | -4.5% | |
| Q1 2023 | -4.4% | -6.1% | -11.9% | |
| Q4 2022 | +11.2% | -1.2% | -3.9% | |
| Q3 2022 | -1.8% | +2.4% | +3.0% | |
| Q3 2021 | -1.8% | +2.4% | +3.0% | |
| Q2 2021 | -5.5% | -5.7% | +12.7% | |
| Q2 2022 | -5.5% | -5.7% | +12.7% | |
| Q4 2021 | +23.4% | +28.2% | +97.5% | |
| Q1 2022 | +23.4% | +28.2% | +97.5% | |
| Q1 2021 | — | — | — | |
| Q4 2020 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro